Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

Jessica Farrell, PharmD, from Albany Medical Center, discusses a 5-year study on the long-term efficacy and safety of switching between upadacitinib and adalimumab in rheumatoid arthritis patients. The study, published in Rheumatology and Therapy, evaluates switch data through 228 weeks, showing comparable outcomes between groups. Jessica breaks down key findings, including clinical remission and low disease activity scores, and highlights important safety considerations for JAK and TNF inhibitors. Learn more on the RhAPP platform, and don't forget to check out additional Journal Club reviews.